Essity's 50-Year Pricing Reflex Meets Its Toughest Test Yet

A Middle East-driven COGS shock, a pension-flattered balance sheet, and the Latin America story quietly flipping from growth engine to restructuring charge

ESSITY-B.ST · Earnings Call · 2026-10-22

The quarter that hid behind the word "resilient"

Essity opened its third-quarter call the way it has opened several now: with the language of endurance. “The third quarter can be -- or it was characterized by resilience and a stable performance in quite a challenging market.” — Ulrika Kolsrud, CEO · 2026-10-22 That framing is not new. A year ago the CEO closed a call by calling resilience "a critical success factor"; nine months ago she opened with "a solid 2025 behind us." When a company reaches for the same adjective every quarter, the interesting question is what the adjective is covering for. This time it is covering for a 150-basis-point group margin contraction driven almost entirely by cost of goods. Reported sales rose 4.1%, but 2.5 points of that was currency and roughly 2 points was the North American Feminine Care acquisition — organic growth was negative 0.3%. Gross margin fell 170bp, of which COGS was 190bp. CFO Fredrik Rystedt quantified it with unusual precision: COGS up about SEK 660 million year-on-year, of which energy was SEK 245 million, raw material close to SEK 420 million, distribution SEK 75 million. Sequentially it was worse still. “if you look at sequential COGS, it was SEK 510 million just in 1 quarter.” — Fredrik Rystedt, CFO · 2026-10-22 And Q4 is guided to be higher again, both year-on-year and sequentially.

The global theme Essity is downstream of

Here is the confluence worth flagging. In the market's own curated keywords, Middle East conflict and high fuel costs were top-ten global themes two quarters ago — energy, diesel, oil, bunker prices all spiking together. That wave has already been voted on by the tape and has faded in the 30-day window. Essity is arriving at it late, because its exposure is indirect and lagged: oil-based superabsorbents and nonwovens flowing into COGS with a four-to-five-month delay, as the CEO explained back in April. So a theme the market has moved past is, for this company, still ahead. The Q3 miss on costs was, per management, smaller than feared — but the Q4 step-up is the one that hasn't landed yet. That is the single most consequential fact in this report. Everything else is texture.

The 50-year reflex, stress-tested

Mid-Q&A, unprompted, Rystedt interrupted a question about the Consumer Tissue divestment to re-litigate the cost debate:

I just want to remind everyone that we always compensate for COGS increases or raw material or energy. We always do that. We've done that for the last 50 years as long as we have checked with price and price alone.
Fredrik Rystedt, CFO · 2026-10-22

That is a defensive reflex, and the prior calls show exactly where it comes from. In July he said the same thing almost verbatim — “we always compensate with price. We will continue with price increases as long as it takes to fully compensate, as we always do.” — Fredrik Rystedt, CFO · 2026-07-16 In April, pressed on margin stability, the CEO attributed it to having “become more agile in our pricing.” — Ulrika Kolsrud, CEO · 2026-04-23 The company has now spent at least three consecutive quarters rehearsing a pricing-power argument it evidently feels is not being believed. The tension is real, not rhetorical. Price/mix for the group was minus 0.2% in the quarter — 0.5 points negative on price, 0.3 positive on mix — because the roll-backs granted in Q4 2025 and Q1 2026 are still annualising. So the company is simultaneously absorbing a fresh cost shock and comping against self-inflicted price concessions. It insists it is raising prices sequentially across all four business areas; the P&L won't show it cleanly until the concessions wash out. Note also the honest scaling of the tariff re-escalation with Canada: roughly 60bp on Professional Hygiene and 20–30bp for the group — the same order of magnitude as the SEK 110 million/SEK 70 million hit disclosed a year ago. This is a recurring, not a new, tax.

Latin America flips from engine to charge

The quietest but most interesting change is geographic. For several quarters, Latin America has been the growth witness — the CEO has praised feminine brands and incontinence there, growing nicely "in what is quite a challenging market." This quarter, Latin America means factory footprint optimization: two smaller production sites closed, production moved into a more efficient footprint, low-value volumes exited, roughly SEK 500 million of cost taken in Q3 against annual savings of only about SEK 150–160 million. Crucially, that restructuring caused 1.2 of the 1.9 points of Consumer Tissue volume decline — and management says it persists through Q4, Q1 and Q2 of 2027. Asked whether it was tied to the strategic review of Consumer Tissue, the CEO was categorical: “no, it's not linked to the strategic review. And yes, we would we would do it anyhow.” — Ulrika Kolsrud, CEO · 2026-10-22 Which is the tell. The company is disentangling shared manufacturing between Professional Hygiene and Consumer Tissue while formally running a sale process — and telling you the disentangling is not the sale process. Preparatory work is being booked as ordinary efficiency. Meanwhile declining volumes in Baby (low birth rates, aggressive promotion) and a Professional Hygiene volume dip of 0.6% on North American distributor destocking are both being described as phasing — a word that spiked into the company's keyword set this quarter. Personal Care is the counterweight: share gains across all three branded categories, and stable volumes at group level, which is arguably a win given the rest.

The AI story nobody is pricing, and the balance sheet nobody should

Essity's genuine novelty is buried in Professional Hygiene. Tork Vision Cleaning now runs in 38 airports, cuts customer cleaning time by up to 25%, and — the important number — half its customers are new to Tork. A BMW plant with 3,500 connected devices is the reference logo. This is an AI-adjacent, sticky, data-and-dispenser business that sells against commoditised base assortment; note that a rival AI keyword cluster globally (AI data center, data center power) has been falling 5–8% over 30 days. Essity's AI pitch is deliberately not that trade. It's the most differentiated thing in the deck, and it got less airtime than the cost bridge. The balance sheet deserves equal scrutiny. Net debt SEK 25 billion, 1.0x EBITDA — aided by a SEK 5.4 billion full-year IFRS pension revaluation from higher rates and good asset returns. Rystedt volunteered the correction: stripped of it, leverage is closer to 1.3x. Cash flow of SEK 5.8 billion was genuinely strong, though working capital benefited from energy hedge derivatives mark-ups as prices rose. And the activist question produced the most carefully worded answer of the call: Cevian, supportive of strategy, not on the board, meeting after results like any other investor.

What to watch

Q4. The COGS step-up is guided bigger than Q3's; the SEK 150 million-plus SG&A savings programme is nearing completion and cannot be leaned on twice; price concessions are still annualising against it. The company's entire credibility rests on a 50-year claim that price always catches cost. This quarter, for the first time in a while, the arithmetic — organic sales negative, price/mix negative, margin down 150bp — does not yet corroborate it. Watch whether the impact from COGS turns into a Q4 margin trough and a Q1 recovery, or into a fourth consecutive call where the same reassurance is repeated rather than demonstrated. Watch, too, whether the market leader framing in incontinence survives a Brazilian retail-channel push — the o.b./Sempre Livre/Carefree deal closes by Q2 2027, and it is the clearest evidence that management still believes portfolio rotation, not price alone, is the answer.